NNPC

Roche: Antibody cocktail diminishes risk of symptomatic COVID-19

one year ago | 41



Nexim
NCC
SWISS pharmaceutical giant, Roche, on Monday presented new data on its phase three trial of an antibody cocktail. The antibody cocktail is meant to reduce the risk of the asymptomatic case of COVID-19, the company said in a statement. The Basel-headquartered company said that its latest data set showed that the subcutaneous administration of a cocktail of casirivimab and imdevimab reduced the risk of an asymptomatic case by 81 percent. “Among individuals, who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom duration,’’ it stated. The company added that a in-group of recently infected asymptomatic patients, the cocktail reduced the risk of progressing to symptomatic COVID-19 by 31 percent. The data would be shared with regulatory authorities in Europe and the United States, the company said. (dpa/NAN) – Apr. 12, 2021 @ 11:44 GMT
ExxonMobil

Readers Comments

0 comment

No comments yet. Be the first to post comment.

Related stories

Recommended for you...

From Twitter